U.S. Patent 5,968,973: Scope, Claims, Expiration, Orange Book Status, and HPV Treatment Patent Landscape

U.S. Patent No. 5,968,973 protected methods of treating papillomavirus-associated hyperplasia, including condyloma acuminata and cervical intraepithelial neoplasia, with tea catechins such as epigallocatechin gallate (EGCG). Its principal commercial relevance was the 15% sinecatechins ointment marketed as Veregen. The patent expired in August 2017, eliminating it as a current barrier to generic or alternative products. The claims remain relevant for historical validity analysis, freedom-to-operate reviews, patent litigation, and evaluation of follow-on formulations.

What does U.S. Patent 5,968,973 cover?

U.S. Patent 5,968,973 covers a therapeutic method, not a catechin compound or composition standing alone. The independent claim requires four core elements:

A human patient.
Hyperplasia caused by a papillomavirus.
Administration of a composition containing a tea catechin.
An amount effective against the hyperplasia.

Claim 1 is the broadest claim. Claim 2 narrows the active ingredient to (-)-epigallocatechin gallate, commonly known as EGCG. The remaining claims narrow the treatment by dosage form, concentration, route, anatomical site, disease manifestation, or administration route.

The patent is associated with the development of green-tea catechin therapy for HPV-related genital lesions and was commercially implemented through sinecatechins ointment.

Patent bibliographic profile

Field	Information
U.S. patent	5,968,973
Title	Treatment of papilloma virus infection
Filing date	August 22, 1997
Earliest priority	August 1996
Publication date	October 19, 1999
Patent type	U.S. utility patent
Claim category	Method of treatment
Core active	Tea catechins, particularly EGCG
Principal disease area	HPV-associated hyperplasia
Commercial product associated with technology	Veregen, sinecatechins 15% ointment
Patent expiration	August 2017
Current status	Expired

The patent term ran for 20 years from the applicable U.S. filing date, subject to any term adjustment reflected in the official patent record. The patent is now expired and cannot provide a current exclusionary right.

How broad is claim 1 of U.S. Patent 5,968,973?

Claim 1 is broad in therapeutic concept but narrower in disease causation than a general anti-viral claim. It does not cover every use of EGCG, every HPV infection, or every treatment of warts.

Claim 1 limitations

Claim element	Scope
“Method for treating”	Requires a therapeutic act directed to treatment
“Hyperplasia”	Requires abnormal tissue proliferation or lesion growth
“Caused by a papilloma virus”	Requires an HPV-related causal connection
“Administering to a human”	Animal and in vitro uses are outside the literal claim
“Composition which comprises a tea catechin”	At least one tea catechin must be present; other ingredients are permitted
“Effective anti-hyperplasia amount”	The amount must be therapeutically effective against the relevant hyperplasia

The word “comprises” creates an open-ended composition limitation. A product containing a tea catechin plus petrolatum, water, preservatives, penetration enhancers, other active ingredients, or excipients could satisfy the composition element if the treatment and disease limitations are met.

The functional phrase “effective anti-hyperplasia amount” does not specify a single concentration. It requires a fact-dependent showing that the administered amount has the claimed therapeutic effect. In litigation, the parties would likely dispute whether the accused dosage and regimen treat HPV-associated hyperplasia rather than merely reduce viral load, inflammation, or symptoms.

What formulations are protected by the patent?

The patent claims ointments and suppositories, but it does not claim a standalone ointment composition independently of use. The formulation limitations operate only within a treatment method.

Ointment claims

Claims 3 and 4 cover treatment using an ointment, with claim 4 requiring EGCG. Claims 7 through 11 add concentration, base, and anatomical-site limitations:

Claims 7 and 8: tea catechin concentration of 2% to 20% or 5% to 20% by weight.
Claim 9: 15% by weight.
Claim 10: a vaseline base forming a cream.
Claim 11: topical application to external genital organs.

The 15% limitation in claim 9 maps closely to the commercial Veregen product, which contains 15% sinecatechins ointment.

Suppository claims

Claims 5 and 6 cover suppository administration, with claim 6 requiring EGCG. Claims 12 through 15 specify:

50 mg to 500 mg of tea catechin per suppository.
200 mg to 300 mg per suppository.
250 mg per suppository.
Vaginal administration.

These claims are directed to a vaginal dosage form and are materially narrower than claim 1.

Anatomical-site claims

Claims 16 through 19 cover topical treatment of:

An infected area generally.
The vagina.
An external genital organ.
The cervix.

The claims do not require a particular HPV genotype. The literal disease scope therefore potentially includes multiple papillomavirus types, provided the claimed hyperplasia is caused by a papillomavirus.

Which disease conditions fall within the claims?

Claims 20 and 21 expressly identify two HPV-associated conditions:

Condyloma acuminata, commonly called genital warts.
Cervical intraepithelial neoplasia, or CIN.

The patent therefore reaches both external genital lesions and cervical pre-neoplastic lesions when the other claim limitations are met. The express listing of these conditions does not necessarily exclude other HPV-caused hyperplasias from claim 1, but it narrows the dependent claims to the identified disease manifestations.

The commercial product associated with the patent was approved for external genital and perianal warts in immunocompetent adults. The FDA-approved indication did not establish approval for CIN, cervical cancer, or all HPV infections. A use outside the approved indication could still implicate a method patent if the statutory claim elements were satisfied, but regulatory approval and patent infringement are separate questions.

Does the patent cover EGCG itself?

No. The patent does not claim EGCG as a chemical compound, nor does it claim all therapeutic uses of EGCG.

Claim 2 covers the method of claim 1 when the tea catechin comprises EGCG. A party could avoid claim 2 by using a tea catechin composition that contains no EGCG, but claim 1 could remain relevant if the composition contains another qualifying tea catechin and satisfies the remaining limitations.

The patent also does not appear, from the supplied claims, to require:

A specific EGCG purity.
A defined catechin ratio.
A particular extraction process.
A specific botanical source beyond the tea-catechin concept.
A particular HPV genotype.
A specific treatment duration.
A particular excipient other than the dependent vaseline limitation.

What is the claim hierarchy?

The claim structure creates several distinct protection layers.

Claims	Subject matter
1	Broad treatment method using a tea catechin
2	Claim 1 using EGCG
3-4	Ointment dosage form, with claim 4 requiring EGCG
5-6	Suppository dosage form, with claim 6 requiring EGCG
7-9	Ointment concentration ranges, including 15%
10-11	Vaseline-based cream applied to external genital organs
12-15	Suppository catechin amounts and vaginal use
16-19	Topical treatment by anatomical site
20	Condyloma acuminata
21	Cervical intraepithelial neoplasia
22	Oral administration

Claim 22 is notable because it expressly covers oral administration, while many of the narrower claims focus on topical, vaginal, ointment, or suppository treatment. Claim 1 itself is not limited to topical therapy.

When did U.S. Patent 5,968,973 lose exclusivity?

The patent expired in August 2017. Expiration ended the patent-based exclusivity for all 22 claims.

Exclusivity timeline

Event	Date or period
Earliest priority	August 1996
U.S. filing	August 22, 1997
U.S. grant	October 19, 1999
Veregen FDA approval	October 31, 2006
Statutory new-drug exclusivity period	Approximately through October 31, 2009
Patent expiration	August 2017
Post-expiration position	No enforceable exclusion under the patent

The patent did not provide a current patent barrier after expiration. Any present-day market protection would need to arise from a different unexpired patent, regulatory exclusivity, trade secret, manufacturing advantage, trademark, or commercial relationship.

What was the Orange Book status of U.S. Patent 5,968,973?

The patent was listed in connection with Veregen, the FDA-approved sinecatechins 15% ointment. Its Orange Book relevance was tied to the approved drug product and the patent’s method-of-use coverage.

The listing did not convert the patent into a composition patent. It identified a patent that the NDA holder represented as covering the approved product or an approved method of use under the Hatch-Waxman framework.

Because the patent expired in 2017:

A current ANDA applicant does not face a live patent term based on U.S. 5,968,973.
A historical Paragraph IV certification could have challenged the patent before expiration.
A current applicant would evaluate the Orange Book listing for procedural completeness and any other listed patents, but this patent alone does not support delayed generic entry.

Were Paragraph IV challenges possible?

Yes. Before expiration, an ANDA applicant seeking approval for a product referencing Veregen could have submitted a Paragraph IV certification asserting that U.S. 5,968,973 was invalid, unenforceable, or not infringed.

A Paragraph IV notice concerning the patent could have triggered patent litigation under 35 U.S.C. § 271(e)(2). If suit was filed within the statutory period, FDA approval could have been stayed for up to 30 months, subject to statutory exceptions and court developments.

After expiration, the patent no longer supports a Paragraph IV-based delay. A generic applicant may still address the patent in its ANDA strategy, but the patent cannot block approval through an unexpired patent right.

No reported landmark federal decision concerning the validity or construction of the 5,968,973 claims is central to the current market. The patent’s commercial importance arose mainly from its relationship to Veregen and its Orange Book listing rather than from a major appellate claim-construction precedent.

What FDA regulatory status is associated with this patent?

The commercial product associated with the patent is Veregen, a 15% sinecatechins ointment. FDA approved Veregen under NDA 21-902 for the topical treatment of external genital and perianal warts in immunocompetent adults.

Regulatory profile

Regulatory item	Status
Product	Veregen
Active ingredient	Sinecatechins
Strength	15% ointment
Dosage form	Topical ointment
FDA pathway	NDA
Approval date	October 31, 2006
Indication	External genital and perianal warts
Patient population	Immunocompetent adults
Patent relationship	U.S. 5,968,973 listed historically
Biosimilar pathway	Not applicable

Sinecatechins is a botanical drug product rather than a biologic. A biosimilar application under the Public Health Service Act is therefore not the expected competitive pathway. Follow-on competition would ordinarily involve an ANDA, a 505(b)(2) application, or a separately supported NDA, depending on the proposed product and differences from the reference product.

How strong was the patent estate?

The estate was commercially strong during the period when the patent remained in force because claim 9 tracked the 15% ointment strength used in Veregen. Its strength was narrower in other respects.

Strengths

Direct coverage of HPV-associated hyperplasia treatment.
Express EGCG coverage.
Specific protection for ointment and suppository dosage forms.
Specific concentration ranges and a 15% concentration.
Coverage of genital, vaginal, cervical, and external genital application.
Alignment between a dependent claim and the marketed 15% ointment.

Limitations

The claims are method claims, not composition claims.
The claims require treatment of a human.
The disease must involve papillomavirus-caused hyperplasia.
The patent does not claim all uses of green-tea extracts.
The patent does not establish protection for a particular manufacturing process.
Many claims depend on demonstrating a clinical therapeutic effect.
The patent expired in 2017.

Before expiration, a competitor could have designed around the claims by changing the active catechin profile, treatment indication, dosage form, concentration, route, or disease target. Design-around analysis would still need to account for claim 1, which is substantially broader than the narrower product-specific claims.

What manufacturing and intellectual-property barriers remain?

U.S. Patent 5,968,973 does not create a current manufacturing barrier. It does not, based on the supplied claims, protect:

Cultivation of tea plants.
A particular extraction solvent.
A purification sequence.
A specific catechin assay.
A stable finished-product process.
A manufacturing site.
A proprietary device.
A package or applicator.

Commercial barriers may remain in the form of botanical raw-material consistency, catechin oxidation control, microbial limits, batch-to-batch standardization, analytical characterization, and formulation stability. Those are regulatory and technical barriers rather than continuing rights under the expired patent.

A newer patent could theoretically protect a distinct formulation, delivery system, extraction method, stabilization system, or combination therapy. Such a patent would need to be analyzed separately from U.S. 5,968,973.

How does Veregen compare with competing HPV treatments?

Product or therapy	Active ingredient	Dosage form	Primary use	Patent position
Veregen	Sinecatechins	15% topical ointment	External genital and perianal warts	5,968,973 expired
Aldara	Imiquimod	5% cream	External genital and perianal warts	Original core exclusivity expired
Zyclara	Imiquimod	3.75% cream	External genital and perianal warts and related indications	Separate formulation and use history
Condylox	Podofilox	0.5% topical solution or gel	External genital warts	Core product exclusivity expired
Cryotherapy or surgical removal	None	Procedure	Lesion removal	No drug patent barrier
HPV vaccination	Recombinant viral antigens	Injection	Prevention, not treatment	Separate biologic patent and regulatory estate

Veregen’s differentiation was its botanical catechin composition and topical ointment dosage form. Imiquimod acts as an immune response modifier, while podofilox is a cytotoxic antimitotic agent. These products are therapeutic competitors, but their patents and regulatory pathways are distinct.

What litigation and settlement issues affected the patent?

The principal legal risk before expiration involved potential ANDA litigation over:

Whether a generic product practiced a claimed method.
Whether the 15% sinecatechins strength fell within the claims.
Whether the proposed labeling induced use for HPV-associated hyperplasia.
Whether the claims were enabled across the full tea-catechin scope.
Whether the claims were obvious in view of prior green-tea, catechin, and HPV literature.
Whether the patent was enforceable after prosecution-history review.

Method-of-use litigation would have focused heavily on the generic label. A generic applicant could seek a “skinny label” that carved out patented indications or directions, but the effectiveness of that strategy would depend on the remaining unpatented uses and the actual labeling and marketing conduct.

No continuing settlement restriction can survive the expiration of the patent as a patent-based market bar. Historical licensing arrangements involving the University of Minnesota, Medigene, and commercial marketers may have affected commercialization, royalties, and supply rights, but those contractual arrangements are separate from patent enforceability.

What is the current generic-entry risk?

The patent-specific generic-entry risk is high because U.S. 5,968,973 expired in 2017. The principal remaining issues are regulatory equivalence and product development rather than patent term.

A follow-on applicant may face:

Demonstration of pharmaceutical equivalence.
Botanical-drug analytical comparability.
Establishment of the same active ingredient profile.
Topical formulation comparability.
Quality and stability requirements.
FDA review of whether an ANDA, 505(b)(2), or full NDA is appropriate.
Other unexpired patents, if any, listed for the reference product or covering a distinct formulation.

The expired patent does not prevent a competing manufacturer from developing a 15% sinecatechins ointment. It also does not prevent alternative topical or oral catechin products, subject to FDA requirements and any unrelated intellectual-property rights.

What geographic coverage did the patent provide?

The patent provided rights in the United States only. It did not directly control European, Japanese, Canadian, or other foreign markets.

The underlying invention may have been pursued through international patent filings or foreign national applications, but foreign rights require separate analysis. Expiration dates, claim scope, prosecution history, supplementary protection rights, and litigation outcomes could differ by country.

A U.S. freedom-to-operate conclusion therefore cannot be extended automatically to:

The European Union.
The United Kingdom.
Canada.
Japan.
China.
Australia.
Latin American markets.

Key Takeaways

U.S. Patent 5,968,973 claimed methods of treating HPV-caused hyperplasia with tea catechins.
Claim 1 is the broadest claim and covers a human treatment method using a tea-catechin-containing composition.
EGCG is specifically covered by claim 2.
Claims 3 through 15 protect ointment and suppository implementations, including 15% ointments and 250 mg suppositories.
Claims 16 through 21 address topical sites and HPV-related conditions such as genital warts and CIN.
Claim 22 covers oral administration.
The patent was historically linked to Veregen, a 15% sinecatechins ointment approved by FDA in 2006.
The patent expired in August 2017.
It no longer creates a current patent barrier to generic entry.
The product is a botanical drug, so biosimilar regulation is not the relevant follow-on pathway.
Current commercial barriers are more likely to involve formulation equivalence, botanical standardization, manufacturing quality, regulatory strategy, and any later-filed patents.

FAQs

Can a company market an EGCG ointment for genital warts after the patent expired?

Yes. U.S. Patent 5,968,973 no longer blocks that activity. The company must still satisfy FDA requirements and avoid infringement of any separate unexpired patent.

Did U.S. Patent 5,968,973 claim treatment of cervical cancer?

No. The supplied claims identify cervical intraepithelial neoplasia, not invasive cervical cancer. Claim 21 is limited to CIN, and claim 1 requires HPV-caused hyperplasia.

Is a 15% sinecatechins product automatically covered by the expired patent?

During the patent term, a 15% product used for the claimed HPV-related treatment could have implicated claim 9 and related claims. After expiration, the patent cannot impose current infringement liability.

Could an oral EGCG product have infringed before expiration?

Potentially. Claim 22 expressly covers oral administration, and claim 1 is not limited to topical use. The product would still need to satisfy the tea-catechin, human-treatment, HPV-caused-hyperplasia, and effective-amount limitations.

Does the patent cover green-tea extract used for unrelated diseases?

No. The claims require treatment of hyperplasia caused by a papillomavirus. Uses for cancer, metabolic disease, inflammation, or other conditions are outside the literal scope of the supplied claims unless another claim or patent applies.

References

U.S. Patent No. 5,968,973. (1999). Treatment of papilloma virus infection. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2006). Veregen (sinecatechins) ointment, 15%: Prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Food and Drug Administration. (2016). Botanical drug development: Guidance for industry. FDA.
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, Pub. L. No. 98-417, 98 Stat. 1585.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	8-321195	Nov 18, 1996

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0842660	⤷ Start Trial	C300581	Netherlands	⤷ Start Trial
European Patent Office	0842660	⤷ Start Trial	C00842660/01	Switzerland	⤷ Start Trial
European Patent Office	0842660	⤷ Start Trial	12C0077	France	⤷ Start Trial
European Patent Office	0842660	⤷ Start Trial	1290030-4	Sweden	⤷ Start Trial
European Patent Office	0842660	⤷ Start Trial	SPC/GB15/042	United Kingdom	⤷ Start Trial
Austria	288266	⤷ Start Trial
Australia	4443897	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,968,973

Summary for Patent: 5,968,973